Prioritize sustainable, long-term growth and value creation over immediate, expedient gains that could damage the business's future. This philosophy guides decisions from product development to strategic planning, ensuring the company builds a lasting competitive advantage instead of chasing fleeting wins.

The proposal to move public companies to semi-annual reporting is a double-edged sword. It could free management from short-term pressure, enabling more ambitious strategies. However, less frequent updates would create larger information gaps, likely leading to more dramatic and volatile stock price swings.

A company's approach to investor relations—whether it focuses on short-term guidance or long-term strategy—acts as a filtering mechanism. It actively attracts an "audience" of shareholders whose time horizon and values mirror management's, as Warren Buffett noted, shaping the stability of the company's investor base.

In an unusually transparent move, Arrow announced a new, conservative approach to financial guidance. Their stated objective is to "meet and beat expectations," effectively telling Wall Street they will now under-promise and over-deliver to rebuild credibility—a refreshingly honest take on the investor relations game.

Public companies, beholden to quarterly earnings, often behave like "psychopaths," optimizing for short-term metrics at the expense of customer relationships. In contrast, founder-led or family-owned firms can invest in long-term customer value, leading to more sustainable success.

The modern market is driven by short-term incentives, with hedge funds and pod shops trading based on quarterly estimates. This creates volatility and mispricing. An investor who can withstand short-term underperformance and maintain a multi-year view can exploit these structural inefficiencies.

The only two useful timeframes for management are the week (long enough to ship and validate ideas) and the decade (long enough for strategic bets to mature). The quarter is an arbitrary, useless middle ground that distracts from what truly matters for long-term value creation.

Post-IPO, credibility is a biotech's most valuable asset. Leaders should "under-promise and over-perform" by avoiding specific quarterly guidance for clinical milestones. Instead, use broader windows like "first half of the year" to build in flexibility, as clinical trials rarely run on a perfect schedule.

A CEO reveals the behind-the-scenes pressure of financial guidance: investors who own the stock often directly tell management teams to provide conservative public guidance to ensure they can beat analysts' estimates. This creates a challenging dynamic, separating operational reality from the manufactured expectations game required by the market.